Compounds > epolamine
Page last updated: 2024-12-07

epolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID76288
CHEMBL ID122581
CHEBI ID48293
SCHEMBL ID8387
MeSH IDM0273758

Synonyms (75)

Synonym
AC-18883
hydroxyethylpyrrolidine
ai3-62298
einecs 220-976-3
2-(1-pyrrolidino)ethanol
2-(1-pyrrolidinyl)ethanol
n-(2-hydroxyethyl)pyrrolidine
n-(beta-hydroxyethyl)pyrrolidine
unii-r3d835xvcr
epolamine [inn]
r3d835xvcr ,
nsc 26883
ec 220-976-3
n-.beta.-hydroxyethylpyrrolidine
nsc-26883
nsc26883
2955-88-6
HEP ,
1-pyrrolidineethanol
inchi=1/c6h13no/c8-6-5-7-3-1-2-4-7/h8h,1-6h
2-pyrrolidin-1-ylethanol
1-(2-hydroxyethyl)pyrrolidine, 97%
n-beta-hydroxyethylpyrrolidine
epolamine
CHEBI:48293 ,
pyrrolidinoethanol
2-pyrrolidinoethanol
1-(2-hydroxyethyl)pyrrolidine
2-(pyrrolidin-1-yl)ethanol
CHEMBL122581
H0479
STK803090
AKOS000120265
1-(2-hydroxyethyl)-pyrrolidine
2-(pyrrolidin-1-yl)ethan-1-ol
A819962
FT-0613402
AM20090391
smr004703280
MLS006011501
BBL027420
SCHEMBL8387
1-(2-hydroxy ethyl)-pyrrolidine
1-(2-hydroxylethyl)pyrrolidine
2-hydroxyethylpyrrolidine
2-pyrrolidine-1-yl-ethanol
n-2-hydroxyethylpyrrolidine
2-pyrrolidin-1-yl-ethanol
1-(2-hydroxy-ethyl)pyrrolidine
2-(pyrrolidine-1-yl)ethanol
n-hydroxyethylpyrrolidine
1-(2-hydroxyethyl) pyrrolidine
pyrrolidin ethanol
2-pyrolidin-1-yl-ethanol
n-(beta-hydroxyethyl)pyrolidine
1-(2-hydroxyethyl)pyrrolidin
2-hydroxyethyl pyrrolidine
2-pyrrolidino-ethanol
1-pyrrolidinoethanol
Q-100373
pyrrolidine-1-ethanol
n-(2-hydroxethyl)pyrrolidine
2-(1-pyrrolidinyl)ethanol #
DTXSID70183733
mfcd00003181
SR-01000944723-1
sr-01000944723
F14228
Q27121124
AS-12255
SB14610
CS-W011235
EN300-20318
HY-W010519
Z104477730

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Fifteen patients experienced a total of 19 adverse events (AEs), 17 of which were mild to moderate, and 2 of which were severe."( Effectiveness and safety of diclofenac epolamine topical patch 1.3% for the treatment of acute pain due to back strain: an open-label, uncontrolled study.
Gimbel, J; Jacobs, D; Paterson, C; Pixton, G, 2011)		0.64
" Fourteen adverse events (none serious) in nine patients (8."( Safety and Efficacy of the FLECTOR (Diclofenac Epolamine) Topical System in Children with Minor Soft Tissue Injuries: A Phase IV Non-randomized Clinical Trial.
Frangione, V; Hoehler, FK; Jones, C; Jones, CA; Ledesma, G; Wisman, PP, 2022)		0.98
"The FLECTOR topical system safely and effectively provided pain relief for minor soft tissue injuries in the pediatric population, with minimal systemic nonsteroidal anti-inflammatory drug exposure and low potential risk of local or systemic adverse events."( Safety and Efficacy of the FLECTOR (Diclofenac Epolamine) Topical System in Children with Minor Soft Tissue Injuries: A Phase IV Non-randomized Clinical Trial.
Frangione, V; Hoehler, FK; Jones, C; Jones, CA; Ledesma, G; Wisman, PP, 2022)		0.98
" This study shows that FDETS can safely and effectively provide pain relief for soft tissue injuries in children, with minimal systemic NSAID exposure and a low potential risk of either local or systemic adverse events."( Safety and Efficacy of the FLECTOR (Diclofenac Epolamine) Topical System in Children with Minor Soft Tissue Injuries: A Phase IV Non-randomized Clinical Trial.
Frangione, V; Hoehler, FK; Jones, C; Jones, CA; Ledesma, G; Wisman, PP, 2022)		0.98

Pharmacokinetics

ExcerptReferenceRelevance
" In this study, [14C]-HEP was administered by oral route (300 mg, about 50 microCi/subject) to 3 volunteers with the aim to investigate its plasma profile and to calculate the relevant pharmacokinetic parameters."( Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers.
Assandri, A; Giachetti, C; Mautone, G; Palumbo, B; Palumbo, R; Tajana, E, )		0.36

Bioavailability

ExcerptReferenceRelevance
"The objective of this work was to design a diclofenac epolamine (DE) flash tablets (FTs) intended to dissolve in the mouth saliva, thereby improving the DE bioavailability and reducing its first-pass liver metabolism."( Fabrication, optimization, and in vitro/in vivo evaluation of diclofenac epolamine flash tablet.
El Sisi, AM; El-Nabarawi, MA; Elshafeey, AH; Mahmoud, DM, 2020)		1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrrolidinesAny of a class of heterocyclic amines having a saturated five-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID158688Inhibitory activity against Plasmodium falciparum1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's2 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index95.63 (26.88)
Search Engine Supply Index2.58 (0.95)

This Compound (50.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
monoisopropanolamine
monoisopropanolamine: possible industrial pollutant; structure. 1-aminopropan-2-ol : Any amino alcohol that is propan-2-ol substituted by an amino group at position 1.		1.9910amino alcohol;
secondary alcohol		Escherichia coli metabolite
betaine
glycine betaine : The amino acid betaine derived from glycine.		1.9910amino-acid betaine;
glycine derivative		fundamental metabolite
cadaverine
[no description available]		1.9910alkane-alpha,omega-diamineDaphnia magna metabolite;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		5.7232amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
meclofenoxate
Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid.		1.9910monocarboxylic acid
2-aminopropanol
2-aminopropanol: RN given refers to cpd without isomeric designation. 2-aminopropan-1-ol : An amino alcohol that is alanine in which the carboxy group has been reduced to the corresponding alcohol.		1.9910amino alcohol;
primary alcohol;
primary amino compound
hexamethonium bromide
[no description available]		1.9910
cetrimonium bromide
cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.		1.9910organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
cysteamine
Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.		1.9910amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride
acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.		1.9910quaternary ammonium salt
2-diethylaminoethanol
2-diethylaminoethanol: RN given refers to unlabeled parent cpd. 2-diethylaminoethanol : A member of the class of ethanolamines that is aminoethanol in which the hydrogens of the amino group are replaced by ethyl groups.		1.9910ethanolamines;
primary alcohol;
tertiary amino compound
deanol
Deanol: An antidepressive agent that has also been used in the treatment of movement disorders. The mechanism of action is not well understood.. N,N-dimethylethanolamine : A tertiary amine that is ethanolamine having two N-methyl substituents.		1.9910ethanolamines;
tertiary amine		curing agent;
radical scavenger
diethanolamine
diethanolamine: RN given refers to parent cpd. diethanolamine : A member of the class of ethanolamines that is ethanolamine having a N-hydroxyethyl substituent.		1.9910ethanolamineshuman xenobiotic metabolite
zephiramine
[no description available]		1.9910
sterogenol
hexadecylpyridinium bromide: structure in first source. cetylpyridinium bromide : A pyridinium salt that has N-hexadecylpyridinium as the cation and bromide as the anion.		1.9910bromide salt;
pyridinium salt		antiseptic drug;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
surfactant
3-amino-1-propanol
3-aminopropan-1-ol : A member of the class of propanolamines that is propane with a hydroxy substituent at C-1 and an amino substituent at C-2, making it both a primary amine and a primary alcohol.		1.9910primary alcohol;
primary amine;
propanolamine
decamethonium dibromide
[no description available]		1.9910
2-amino-2-methyl-1-propanol
2-amino-2-methyl-1-propanol: RN given refers to parent cpd		1.9910
3,3-dimethylbutan-1-ol
3,3-dimethylbutan-1-ol: structure		1.9910
dodecyltrimethylammonium bromide
dodecyltrimethylammonium bromide : A quarternary ammonium cation having one dodecyl and three methyl substituents around the central nitrogen.		1.9910bromide salt;
quaternary ammonium salt		surfactant
2-amino-1-butanol
2-amino-1-butanol: structure		1.9910
serinol
serinol: RN given refers to cpd without isomeric designation		1.9910
diclofenac hydroxyethylpyrrolidine
[no description available]		4.7211organic salt
ConditionIndicatedRelationship StrengthStudiesTrials
Injuries, Soft Tissue
[description not available]		04.7211
Acute Pain
Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.		010.4122
Back Ache
[description not available]		03.4511
Back Pain
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.		03.4511